Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium
Alzheimer's & Dementia · 2025-10 · 21 (10)
DOI: 10.1002/alz.70752 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Alzheimer's & Dementia, online erschienen am 30.09.2025. Verfasst von Inge M W Verberk und 19 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Specimen Handling, Blood Specimen Collection. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: research grants of Health Holland and ZonMW, Pasman Stichting. Research of Alzheimer Center Amsterdam, Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Blood‐based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre‐analytical stability requires scrutiny. This study assessed pre‐analytical effects to inform a standardized sample handling protocol. METHODS Assessed pre‐analytical variations included collection tube type, hemolysis, centrifugation settings, centrifugation/storage delays, tube transfers, and freeze‐thawing ( n = 15/experiment). Phosphorylated tau (pTau) isoforms were measured with Simoa, Lumipulse, MesoScale Discovery, and immunoprecipitation‐mass spectrometry. Amyloid‐beta (Aβ42, Aβ40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) protein were measured with Simoa. RESULTS All assessed BBM levels varied by over 10% by collection tube type. Aβ peptides were the most sensitive, and their levels declined >by more than 10% under storage and centrifugation delays, more steeply at room temperature (RT) compared with 2°C to 8°C. NfL and GFAP levels increased by more than 10% upon RT/−20°C storage. pTau isoforms demonstrated stability across most pre‐analytical variations. DISCUSSION We established an evidence‐based handling protocol to ensure reliable sample handling for neurological BBMs upon adoption in clinics, trials, and research. Highlights Sample handling protocols can mitigate pre‐analytical effects on BBM results. We developed an evidence‐based, expert‐consensus plasma sample handling protocol. Primary collection tube and delays to centrifuging or freezing impact AD BBMs. Plasma pTau217 is highly resistant to pre‐analytical sample handling variations. Plasma Aβ42 and Aβ40 were most sensitive to pre‐analytical variations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
- Department of Computing and Information Sciences, Department of Biology, AI Technology for Life, Utrecht University, Utrecht, the Netherlands.
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
- Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
- Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Lund, Sweden.
ORCID-Profile: Mariam Gouda
Förderung
- research grants of Health Holland and ZonMW
- Pasman Stichting. Research of Alzheimer Center Amsterdam
- Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam
- Swedish Research Council
- Swedish Alzheimer Foundation
- Hjärnfonden, Sweden
- European Union Joint Program for Neurodegenerative Disorders
- Alzheimer's Association 2021 Zenith Award
Zitieren
APA
Verberk, I. M. W., Gouda, M., Antwi-Berko, D., van Leeuwenstijn, M., Bongers, B., Houtkamp, I. M., van der Flier, W. M., Janelidze, S., Hansson, O., Bastard, N. L., Vandijck, M., Hunter, J., Honigberg, L., Kirmess, K. M., Verghese, P. B., Blennow, K., Zetterberg, H., Meyers, E. A., Edelmayer, R. M., & Teunissen, C. (2025). Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70752
Vancouver
Verberk IMW, Gouda M, Antwi-Berko D, van Leeuwenstijn M, Bongers B, Houtkamp IM, et al. Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70752
BibTeX
@article{Verberk2025,
author = {Verberk, Inge M W and Gouda, Mariam and Antwi-Berko, Daniel and van Leeuwenstijn, Mardou and Bongers, Bram and Houtkamp, Isabel M and van der Flier, Wiesje M and Janelidze, Shorena and Hansson, Oskar and Bastard, Nathalie Le and Vandijck, Manu and Hunter, Jacob and Honigberg, Lee and Kirmess, Kristopher M and Verghese, Philip B and Blennow, Kaj and Zetterberg, Henrik and Meyers, Emily A and Edelmayer, Rebecca M and Teunissen, Charlotte},
title = {Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {10},
doi = {10.1002/alz.70752}
}
EUVIMED